Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

Texas MPN Workshop 2022 | COVID-19 and MPNs: updates from the ELN study

Tiziano Barbui • 10 Nov 2022
Texas MPN Workshop 2022
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Interferon

Tiziano Barbui, MD, Bergamo Hospital Research Foundation, Bergamo, Italy, gives a presentation on COVID-19 in patients with myeloproliferative neoplasms (MPNs) and updates from the ELN study at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Tiziano Barbui

New guidelines for the treatment and management of polycythemia vera
10:20
New guidelines for the treatment and management of polycythemia vera
Tiziano Barbui • 6 Oct 2022
The management of polycythemia vera with cytoreductive drug therapy
4:10
The management of polycythemia vera with cytoreductive drug therapy
Tiziano Barbui • 22 Aug 2022
The impact of ruxolitinib on the long-term survival of patients with MF
3:24
The impact of ruxolitinib on the long-term survival of patients with MF
Tiziano Barbui • 22 Aug 2022
COVID-19 and MPN updates
6:00
COVID-19 and MPN updates
Tiziano Barbui • 22 Aug 2022

Related Videos

Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Tiziano Barbui • 7 Dec 2025
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Tiziano Barbui • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Tiziano Barbui • 6 Dec 2025
The management of patients with ET or PV during pregnancy
3:32
The management of patients with ET or PV during pregnancy
Tiziano Barbui • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals